Brief Report

Administration of high-dose interleukin-2 in a 2-year-old with metastatic melanoma†

  1. M. Brooke Bernhardt PharmD1,*,
  2. M. John Hicks MD2,
  3. Alberto S. Pappo MD3

Article first published online: 3 SEP 2009

DOI: 10.1002/pbc.22255

Issue

Pediatric Blood & Cancer

Pediatric Blood & Cancer

Volume 53, Issue 7, pages 1346–1348, 15 December 2009

Additional Information

How to Cite

Bernhardt, M. B., Hicks, M. J. and Pappo, A. S. (2009), Administration of high-dose interleukin-2 in a 2-year-old with metastatic melanoma. Pediatric Blood & Cancer, 53: 1346–1348. doi: 10.1002/pbc.22255

Author Information

  1. 1

    Department of Pharmacy, Texas Children's Hospital, Houston, Texas

  2. 2

    Department of Pathology, Texas Children's Hospital, Houston, Texas

  3. 3

    Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas

*Texas Children's Hospital, 6621 Fannin Street, Mail Code 2-2510, Houston, TX 77030.

  1. †

    The authors report no relevant conflicts of interest or financial affiliations.

Publication History

  1. Issue published online: 9 OCT 2009
  2. Article first published online: 3 SEP 2009
  3. Manuscript Accepted: 27 JUL 2009
  4. Manuscript Received: 2 JUN 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (58K)

Keywords:

  • aldesleukin;
  • melanoma;
  • rare tumors

Abstract

Malignant melanoma is rare in pediatrics, and therapies for patients with disseminated disease have not been well studied. This report describes our experience with the use of high-dose interleukin 2 (aldesleukin, IL-2) in a 2-year-old child with metastatic melanoma and describes our approach for the administration of this agent to young patients. Pediatr Blood Cancer 2009; 53:1346–1348. © 2009 Wiley-Liss, Inc.

View Full Article (HTML) Get PDF (58K)